国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2014年
13期
1946-1948
,共3页
噻氯吡啶%低分子肝素%急性脑梗死
噻氯吡啶%低分子肝素%急性腦梗死
새록필정%저분자간소%급성뇌경사
Ticlopidine%Low molecular weight heparin%Acute cerebral infarction
目的 观察噻氯吡啶联合低分子肝素治疗急性脑梗死的临床效果.方法 将100例急性脑梗死患者随机均分为两组,治疗组50例给予噻氯吡啶,每天2次,每次250 mg,同时皮下注射低分子肝素80 IU/kg,每天2次,间隔12小时;对照组50例仅给予噻氯吡啶,每天2次,每次250mg.14天1个疗程,治疗组和对照组的其他治疗均相同.治疗前后对患者的神经功能(ESS)和日常生活活动能力指数(Bathel指数)进行评定,同时检测并记录患者血液流动学指标的变化.结果 治疗组ESS评分及日常生活活动能力指数变化都比对照组大,差异有统计学意义(P<0.01);两组治疗后血液中血小板、纤维蛋白原和血浆黏度的差异均有统计学意义(P<0.01).结论 噻氯吡啶联合低分子肝素治疗急性脑梗死能有效控制病情的发展,使临床疗效得到提高,应大力推广.
目的 觀察噻氯吡啶聯閤低分子肝素治療急性腦梗死的臨床效果.方法 將100例急性腦梗死患者隨機均分為兩組,治療組50例給予噻氯吡啶,每天2次,每次250 mg,同時皮下註射低分子肝素80 IU/kg,每天2次,間隔12小時;對照組50例僅給予噻氯吡啶,每天2次,每次250mg.14天1箇療程,治療組和對照組的其他治療均相同.治療前後對患者的神經功能(ESS)和日常生活活動能力指數(Bathel指數)進行評定,同時檢測併記錄患者血液流動學指標的變化.結果 治療組ESS評分及日常生活活動能力指數變化都比對照組大,差異有統計學意義(P<0.01);兩組治療後血液中血小闆、纖維蛋白原和血漿黏度的差異均有統計學意義(P<0.01).結論 噻氯吡啶聯閤低分子肝素治療急性腦梗死能有效控製病情的髮展,使臨床療效得到提高,應大力推廣.
목적 관찰새록필정연합저분자간소치료급성뇌경사적림상효과.방법 장100례급성뇌경사환자수궤균분위량조,치료조50례급여새록필정,매천2차,매차250 mg,동시피하주사저분자간소80 IU/kg,매천2차,간격12소시;대조조50례부급여새록필정,매천2차,매차250mg.14천1개료정,치료조화대조조적기타치료균상동.치료전후대환자적신경공능(ESS)화일상생활활동능력지수(Bathel지수)진행평정,동시검측병기록환자혈액류동학지표적변화.결과 치료조ESS평분급일상생활활동능력지수변화도비대조조대,차이유통계학의의(P<0.01);량조치료후혈액중혈소판、섬유단백원화혈장점도적차이균유통계학의의(P<0.01).결론 새록필정연합저분자간소치료급성뇌경사능유효공제병정적발전,사림상료효득도제고,응대력추엄.
Objective To study the clinical effect of Ticlopidine combined with low molecular weight heparin (LMWH) in the treatment of acute cerebral infarction (ACI).Methods 100 cases of ACI were randomly divided into two groups.50 patients in treatment group were given Ticlopidine (250 mg,twice a day) and LMWH (80 IU/kg,twice a day); while 50 patients in control group were given only Ticlopidine (250 mg,twice a day),2 weeks as a course of treatment.Evaluated the change of patients' ESS grade,Bathel index and hemorheology after treatment.Result There were statistically significant difference in the change of ESS grade,Bathel index and hemorheology between two groups (P < 0.01).Conclusion The clinical effect of Ticlopidine combined with low molecular weight heparin in the treatment of ACI is obviously,which can control the progression of disease and should be popularized in clinic.